Published in Vaccine Weekly, June 27th, 2012
Walvax Biotechnology Co, Ltd., founded in 2001, specializes in research & development, production and marketing of bio-pharmaceutical vaccines. In September 2010, it went public on the Shenzhen's Growth Enterprise Market (GEM), with the approval of China Securities Regulatory Commission (CSRC). Walvax Biotechnology employs about 863 people, including 161 for research...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2012-06-27)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.